• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Titan Pharmaceuticals Inc.

    5/2/25 4:11:23 PM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TTNP alert in real time by email
    DEFA14A 1 titanpharma_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    (Rule 14a-101)

     

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material under §240.14a-12

     

    Titan Pharmaceuticals, Inc.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Persons(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    2025 TI T AN PHARMACEUTICALS, INC. Signature Signature, if held jointly Date , 2025. Pleas e sig n exactl y a s you r nam e appear s belo w . Whe n share s ar e hel d b y join t tenants , eac h shoul d sign . Whe n signin g a s attorne y , executo r, administrato r, trustee, guardian , corporat e o f fice r , o r partne r, pleas e giv e ful l titl e a s such. Please mark your votes lik e this X 19730 2 T ita n Pharma Proxy Car d Rev 3 Front CONTRO L NUMBER PROXY TH E BOAR D O F DIREC T OR S RECOMMEND S A VOT E FO R PROPOSAL S 1 , 2 , 3 , 4 AN D 5 , AN D FO R “ TW O YEAR S ” A S TH E FREQUENC Y FO R WHIC H S T OCKHOLDER S WIL L H A V E A VOT E O N EXECUTIV E COMPENS A TIO N . 4 . R A TIFIC A TION OF ENROME LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUN T ANT S FOR THE FISCAL YEAR ENDING DECEMBE R 31 , 2025. 5 . APPRO V A L OF OUR EXECUTIVE COMPENS A TION (S A Y - ON - P A Y). 6 . FREQUENCY OF S A Y - ON - P A Y VOTE. FOL D HER E • D O NO T SE P AR A T E • INSER T I N ENVELOP E PROVIDE D PLEAS E MARK , SIGN , D A T E AN D RETUR N TH E PROXY CAR D PROMPT L Y USIN G TH E ENCLOSE D ENVELOP E . a s if yo u marked , signe d an d returne d you r proxy card . V otes submitte d electronicall y over the Internet mus t be receive d by 1 1 : 5 9 p . m . , Eastern T ime, on Jun e 15 , 2025 . INTERNET ww w .cstproxyvote.com Us e the Internet to vote your prox y . Hav e your prox y card availabl e when you acces s the abov e website . Follow the prompt s to vote your shares. MOBILE VOTING On your Smartphone / T ablet , ope n the QR Reade r an d scan the belo w image. Once the voting site i s displayed , enter your Contro l Numbe r from the proxy card an d vote your shares. MAIL – Mark, sign an d dat e your proxy card an d return i t i n the postage - paid envelop e provided. ELECTION OF DIREC T ORS 1. APPRO V A L O F TH E 2015 PLAN AMENDMEN T . 3. V ot e b y Internet , Smartphon e o r T able t - QUIC K EAS Y IMMEDI A T E - 2 4 Hour s a Da y , 7 Day s a W ee k o r b y Mail Y our Mobile or Internet vot e authorize s the named proxies to vot e you r share s in the sam e manner Nominees: A vraham Ben - Tzvi Brynner Chiam Francisco Osvaldo Flores Garcia Firdauz Edmin Bin Mokhtar Gabriel Loh FOR al l nominees liste d a t lef t (except a s marked to the contrary below) WITHHOLD AUTHORITY to vote for al l nominees liste d a t left INSTRUCTION : T o withhol d authorit y t o vot e fo r an y nominee, writ e th e nominee ’ s nam e i n th e spac e provide d belo w . PLEASE D O NO T RETUR N THE PROXY CARD IF YOU AR E VOTING ELECTRONICAL L Y . YOUR VOTE IS IMPOR T AN T . PLEASE VOTE T OD A Y . FOR AGAINST ABS T AIN FOR AGAINST ABS T AIN FOR AGAINS T ABS T AIN FOR AGAINS T ABS T AIN EVE R Y ONE YEAR EVE R Y TWO YEARS EVE R Y THREE YEARS ABS T AIN APPRO V A L O F TH E ISSUANCE PROPOSA L . 2.

     

     

     

     

    2025 FOL D HER E • D O NO T SE P AR A T E • INSER T I N ENVELOP E PROVIDE D THIS PROXY IS SOLICITED ON BEHAL F OF THE BOAR D OF DIREC T ORS PROXY FOR THE ANNUA L MEETING OF S T OCKHOLDERS OF TI T A N PHARMACEUTICALS, INC. T O B E HEL D ON JUN E 16 , 2025 The undersigne d appoint s Cha y W ee i Jye an d Brynner Chiam , an d eac h o f them, attorney s and agent s wit h full powe r o f substitution, i s hereb y authorize d to vote al l o f the shares o f common stock o f T ita n Pharmaceuticals, Inc . (the “Company”) whic h the undersigne d woul d b e entitle d to vote, if personall y present , a t the upcomin g Annual Meeting o f Stockholders o f the Compan y scheduled to be held at the offices of Olshan Frome W olosky LL P , located at 1325 A venue of the Americas, 15 th Floo r , New Y ork, New Y ork 10019 on Monda y , June 16 , 2025 at 9 : 00 a . m . (EST) (including any adjournments o r postponement s thereof an d an y meeting called i n lie u thereof, the “Annual Meeting”) . The und ersigned hereb y revokes an y prox y o r proxie s heretofor e give n an d acknowledge s receipt o f a copy o f the Notic e o f Meeting an d Proxy Statement an d a copy o f the Company ’ s Annual Repor t on Form 10 - K (without exhibits) for the fiscal year ended December 31 , 2024 . IF N O DIRECTIO N IS INDIC A TED WITH RESPEC T T O THE PROPOSALS ON THE REVERSE , THIS PROXY WILL B E VOTED “FOR AL L NOMINEES ” WITH RESPEC T T O PROPOSAL 1 AN D “FOR” PROPOSALS 2 , 3 , 4 AN D 5 AN D FOR “EVE R Y TWO YEARS” A S THE FREQUENCY FOR WHICH S T OCKHOLDERS WILL H A VE A VOTE ON EXECUTIVE COMPENS A TION . IMPOR T AN T : PLEASE SIGN, D A TE AN D MAIL THIS PROXY CAR D PROMPT L Y! CONTINUE D AN D T O B E SIGNED ON REVERS E SIDE 19730 2 T ita n Pharma Proxy Car d Rev 3 Back Important Notic e Regardin g the A vailabilit y of Proxy Materials for the Annua l Meeting of Stockholders Of T itan Pharmaceuticals, Inc. to be held on Jun e 16 , 2025 The proxy statemen t is availabl e at https://ww w .cstprox y .com/titanpharm/am2025

     

     

    Get the next $TTNP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TTNP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TTNP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Loh Gabriel claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      5/5/25 1:50:21 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Jye Chay Weei claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      4/16/25 3:49:51 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Mokhtar Firdauz claimed no ownership of stock in the company (SEC Form 3)

      3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)

      4/5/24 10:14:05 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Leadership Updates

    Live Leadership Updates

    See more
    • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

      NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

      11/27/24 4:05:55 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

      SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut

      10/16/23 4:37:23 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    SEC Filings

    See more
    • SEC Form 425 filed by Titan Pharmaceuticals Inc.

      425 - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      6/3/25 5:25:48 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      6/3/25 5:25:13 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)

      6/2/25 5:20:12 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

      NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) ("TalenTec"), which includes Titan's preliminary proxy statement (the "Form F-4") As previously announced on August 19, 2024, Titan and TalenTec have entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination, pursuant to which Titan will be combined with TalenTec in a

      6/3/25 8:45:44 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

      NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series B Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock for an aggregate purchase price of $1,000,000. The shares have a conversion price of $3.00. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "bl

      4/11/25 4:15:09 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

      NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

      11/27/24 4:05:55 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Titan Pharmaceuticals upgraded by Maxim Group with a new price target

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

      2/25/21 10:45:32 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals upgraded by Maxim Group

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy

      2/18/21 8:31:20 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Titan Pharmaceuticals upgraded by Maxim Group with a new price target

      Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00

      2/18/21 7:31:23 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TTNP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc.

      SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      8/21/24 8:32:38 AM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc. (Amendment)

      SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      4/5/24 4:34:04 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Titan Pharmaceuticals Inc.

      SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

      10/4/23 5:30:18 PM ET
      $TTNP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care